<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> depletes ATP and initiates cascades leading to irreversible tissue injury </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="17154">Nicotinamide</z:chebi> is a precursor of <z:chebi fb="0" ids="13389">nicotinamide adenine dinucleotide</z:chebi> (<z:chebi fb="0" ids="13389">NAD</z:chebi>+) which increases neuronal ATP concentration and protects against malonate-induced neurotoxicity, trauma and nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> toxicity </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore examined whether <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> could protect against <z:hpo ids='HP_0001297'>stroke</z:hpo>, using a model of permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (<z:chebi fb="70" ids="34342">MCA</z:chebi>) occlusion in Wistar rats </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="17154">Nicotinamide</z:chebi> reduced neuronal infarction in a dose-specific manner </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> (500 mg/kg) reduced <z:mpath ids='MPATH_124'>infarcts</z:mpath> when administered up to 2 h after the <z:hpo ids='HP_0003674'>onset</z:hpo> of permanent <z:chebi fb="70" ids="34342">MCA</z:chebi> occlusion </plain></SENT>
<SENT sid="5" pm="."><plain>The mechanism of action underlying the neuroprotection observed with <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> remains to be clarified </plain></SENT>
<SENT sid="6" pm="."><plain>These results are potentially important since <z:chebi fb="0" ids="17154">nicotinamide</z:chebi> is already used clinically, though not in the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
</text></document>